| Dear Voornaam,
The UK government recently announced a planned increase in the skilled worker visa salary threshold and other immigration system changes this year. We are aware that this change may have implications for research staff.
We're looking into how this might affect researchers in our institutes and on our funding programmes, and we're speaking with colleagues in other research organisations. It is too early to fully understand the proposed changes, but we plan to share an update of our understanding on this in early 2024. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
LARS ERWIG JOINS CDD We've announced that Dr Lars Erwig will be joining us as the new director of our Centre for Drug Development. Lars will be responsible for shaping our portfolio of first-in-human trials, which currently includes 10 small molecules and 13 biotherapeutic agents. He will work closely with our academic research community as well as partners across the pharmaceutical and biotech industries.
Lars joins from Johnson & Johnson and previously worked for Galvani Bioelectronics and GSK. Before moving to industry, he was professor of nephrology at the University of Aberdeen, publishing extensively on the role of macrophages in inflammation and host pathogen interactions. His experience in the academic, pharmaceutical and biotechnology sectors will be key to progressing potential treatments for cancer patients through the clinic.
Lars will start on 1 February 2024.
|
|
|---|
|
|---|
|
|
THE UK'S ASSOCIATION TO HORIZON EUROPE OFFICIALLY CONFIRMED The UKs association with Horizon Europe - the EUs flagship funding scheme for scientific research - was officially sealed on 4 December. UK researchers and innovators will be able to participate fully in the Horizon Europe programme on the same terms as researchers from other associated countries (including leading consortia) from the 2024 Work Programmes onwards. The UK Government's Horizon Europe guarantee remains active and covers all remaining Horizon Europe grant calls up to and including work programme 2023, irrespective of the call closing or grant signature date.
Sign up to receive updates about Horizon Europe funding opportunities, news and events related to your areas of interest. |
|
|---|
|
|---|
|
|
EARLY BIRD DISCOUNT ENDING SOON: REGISTER FOR OUR DATA-DRIVEN CANCER RESEARCH CONFERENCE 2024 Are you keen to explore data-enabled cancer research and its potential to drive discovery, innovation and public benefit? Our data-driven cancer research conference in Manchester on 27-28 February is a must-attend event for you.
After an extraordinary number of submissions, abstract submissions are now closed. You can still register before 15 December at our discounted early bird rate to save 40%.
We hope to see you there for the opportunity to develop new collaborations between researchers, clinicians, patient advocates, members of the public, funders and industry.
|
|
|---|
| CO-DESIGNED CROSS-FUNDER SEX AND GENDER POLICY FRAMEWORK AVAILABLE FROM 2024 Over the past few months, Cancer Research UK has been part of a cross-funder group known as MESSAGE (Medical Science Sex and Gender Equity) which has designed a policy framework on sex and gender for clinical and preclinical research.
The new framework will be available from 2024 and will cover sex and gender in research design, implementation, analysis and reporting to help the understanding of relevant sex and gender differences in cancer.
|
|
|---|
|
|---|
|
|
ANNALISA JENKINS AND CHRISTOPH LENGAUER JOIN THE CANCER RESEARCH HORIZONS BOARD Our innovation arm, Cancer Research Horizons, has announced that Annalisa Jenkins and Christoph Lengauer have joined its board. Christoph Lengauer will also take the inaugural chair of the Therapeutic Innovation board.
Annalisa Jenkins is a life-sciences thought leader with over 25 years experience in the industry. She currently has advisory positions at Genomics England, the Kings Fund and the British Heart Foundation, and is a board member of several growing biotech companies including Oncimmune, COMPASS Pathways and Mereo Biopharma.
Christoph Lengauer recently cofounded Curie.Bio, a venture capital firm that offers biotech startups mentorship as well as seed capital. He comes from a research background, making several breakthroughs in the molecular genetics of cancer during his time in the Vogelstein lab, Johns Hopkins University, before leading drug discovery departments at Sanofi and Novartis. |
|
|---|
|
|---|
|
|
NEW IN CANCER CELL: UK-DEVELOPED NEW DRUG IN BLOOD CANCERS TREATMENT A new study published in Cancer Cell reports on the therapeutic mechanism of inobrodib, a new type of oral treatment currently being evaluated in haematological malignancies. Professor Tim Somervaille (Cancer Research UK Manchester Institute) collaborated with CellCentric, a UK-based biotechnology company and other pre-clinical and clinical practitioners to carry out the study.
The study demonstrates inobrodibs action as a potent and selective inhibitor of the bromodomains of p300 and CBP, and it shows inobrodibs profound impact on the regulatory elements which control expression of key cancer driver genes.
Researchers treated a wide panel of cell lines derived from patients with acute myeloid leukemia (AML) and myeloma, and found that the inhibitor was able to reduce the growth of these cells. Further, they used the inhibitor in a series of mouse models and saw changes in the growth of tumours. This paper also reports the first use of this drug in patients, where it was well-tolerated with few side-effects.
In the next phase of the drugs development, it is being tested in combination with other standard-of-care agents in blood cancers such as acute myeloid leukaemia, myeloma and lymphoma.
|
|
|---|
| FREE CONFERENCE ON BREAST CANCER RESEARCH AMONG BLACK WOMEN IN MANCHESTER Register now for the Breast Cancer Research among Black Women Conference 2024 on 12 March 2024 in Manchester. The conference is hosted by The University of Manchester and Manchester Cancer Research Centre.
Join the conference for discussions on breast cancer among Black women and to explore strategies to enhance their involvement in research, access to care and overall health outcomes.
Submit an abstract for a poster or oral presentation by 15 January 2024 to showcase your work alongside patients and the public.
|
|
|---|
|
|---|
|
|
Q&A WITH CAREER ESTABLISHMENT GRANT AWARDEE, MIRJANA EFREMOVA Mirjana Efremova at the Barts Cancer Institute has been awarded a 1m Cancer Research UK Career Establishment Award, supporting her to grow her lab and progress to the next phase of her research career.
Mirjana investigates bowel cancer metastasis and resistance to chemotherapy using computational techniques to study cells in the tumour microenvironment, examine gene expression and epigenetics.
In a recent Q&A, Mirjana talks about her journey into science and starting a lab, what research questions shes tackling, and how this grant is helping her expand her team and advance her research. |
|
|---|
| JOIN OUR 9-MONTH MEDTECH/AI ACCELERATOR PROGRAMME Do you want to translate your early-stage technology or idea into a successful health-tech venture that aims to address an unmet need for cancer patients? Join our Cancer Tech Accelerator to receive guidance on advancing your innovative technology.
The 9-month programme includes a 5-day bootcamp, workshops, interactive sessions and concentrated learning. You will learn how to form an investor-ready start-up to improve cancer patient detection, diagnosis or treatment.
The programme is run in collaboration with Capital Enterprise, Blood Cancer UK, LifeArc, The Brain Tumour Charity, Roche and HGF Limited.
Apply by February 16, 2024. |
|
|---|
|
|---|
|
|
MOV18 THE JOURNEY BEHIND A POTENTIAL IMMUNOTHERAPY GAMECHANGER The journey to get the first IgE anti-cancer drug into a human was certainly not easy.
We follow Sophia Karagiannis and James Spicer from Kings College London on an immunological adventure as they work with our Centre for Drug Discovery on this potentially ground-breaking new class of drug.
Industry, says James, was either afraid of this or didnt understand.
Follow along with the 25-year adventure from a dream to a trial, and how we are supporting innovative projects like this.
|
|
|---|
|
|---|
|
|
| | | London, UK 17 January 2024 |
|
|---|
|
|---|
| | | Manchester, UK 27 February 2024 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
